Ratings by Credit Suisse (Vamil Divan)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 9/17/2019 | Alder Biopharm | ALDR | Maintain | Neutral (N/A) |
|
Details | ||
| 7/10/2019 | Alder Biopharm | ALDR | New Coverage | Neutral (N/A) |
11.43 (18.88) |
65.18% | Details | |
| 7/10/2019 | AcelRx Pharmaceuticals | ACRX | New Coverage | Outperform (N/A) |
2.71 (2.42) |
-10.7% | Details | |
| 7/10/2019 | Portola Pharmaceuticals | PTLA | New Coverage | Neutral (N/A) |
25.98 (25.50) |
-1.85% | Details | |
| 5/6/2019 | Pfizer | PFE | Maintain | Outperform (N/A) |
|
Details | ||
| 4/26/2019 | Alkermes | ALKS | Maintain | Underperform (N/A) |
|
Details | ||
| 4/15/2019 | Allergen | AGN | Maintain | Neutral (N/A) |
|
Details | ||
| 3/22/2019 | Ironwood Pharmaceuticals | IRWD | Maintain | Neutral (N/A) |
|
Details | ||
| 3/22/2019 | Eli Lilly | LLY | Maintain | Neutral (N/A) |
|
Details | ||
| 3/7/2019 | Allergen | AGN | Maintain | Neutral (N/A) |
|
Details | ||
| 3/4/2019 | Aimmune Therapeutics | AIMT | Maintain | Outperform (N/A) |
|
Details | ||
| 3/4/2019 | Portola Pharmaceuticals | PTLA | Maintain | Neutral (N/A) |
|
Details | ||
| 3/4/2019 | Aimmune Therapeutics | AIMT | Maintain | Outperform (N/A) |
|
Details | ||
| 2/15/2019 | AcelRx Pharmaceuticals | ACRX | New Coverage | Outperform (N/A) |
2.63 (2.71) |
3.04% | Details | |
| 2/7/2019 | Eli Lilly | LLY | Maintain | Neutral (Neutral) |
|
Details | ||
| 1/31/2019 | Allergen | AGN | Downgrade | Neutral (Outperform) |
145.12 (193.02) |
33.01% | Details | |
| 1/31/2019 | Pfizer | PFE | Upgrade | Outperform (Neutral) |
40.77 (28.07) |
-31.15% | Details | |
| 1/28/2019 | Johnson & Johnson | JNJ | Maintain | Outperform (N/A) |
|
Details | ||
| 12/13/2018 | Alkermes | ALKS | Downgrade | Underperform (Outperform) |
34.47 (48.33) |
40.21% | Details | |
| 11/8/2018 | Portola Pharmaceuticals | PTLA | Maintain | Neutral (N/A) |
|
Details | ||
| 11/7/2018 | Ironwood Pharmaceuticals | IRWD | Downgrade | Neutral (Outperform) |
14.13 (10.18) |
-27.95% | Details | |
| 11/6/2018 | Alder Biopharm | ALDR | Maintain | Neutral (N/A) |
|
Details | ||
| 11/5/2018 | Abbvie | ABBV | Maintain | Underperform (N/A) |
|
Details | ||
| 10/31/2018 | Pfizer | PFE | Maintain | Neutral (N/A) |
|
Details | ||
| 10/31/2018 | Allergen | AGN | Maintain | Outperform (N/A) |
|
Details | ||
| 10/26/2018 | Galapagos NV | GLPG | Maintain | Neutral (N/A) |
|
Details | ||
| 10/24/2018 | Alkermes | ALKS | Maintain | Outperform (N/A) |
|
Details | ||
| 10/11/2018 | Merck | MRK | Maintain | Outperform (N/A) |
|
Details | ||
| 9/17/2018 | Teva Pharma | TEVA | Maintain | Neutral (N/A) |
|
Details | ||
| 8/27/2018 | Portola Pharmaceuticals | PTLA | Upgrade | Neutral (Underperform) |
25.83 (25.98) |
0.58% | Details | |
| 8/13/2018 | Alder Biopharm | ALDR | Maintain | Neutral (N/A) |
|
Details | ||
| 8/13/2018 | Aimmune Therapeutics | AIMT | Maintain | Outperform (N/A) |
|
Details |
